Thursday, June 03, 2021 10:52:47 AM
Thanks.
As expected, many MRK shareholders sold OGN this morning.
What an opportunity for those of us who see real value in an independent company focused on women's health products.
It's global (only 22% in US), has diversified product lines and, most importantly, the management/Board team have first rate credentials.
If you lack the cash, it may be a a good idea to sell some MRK shares to buy more of this underpriced gem than you received in the spin-off.
Just an opinion. No promises, etc., etc.
As expected, many MRK shareholders sold OGN this morning.
What an opportunity for those of us who see real value in an independent company focused on women's health products.
It's global (only 22% in US), has diversified product lines and, most importantly, the management/Board team have first rate credentials.
If you lack the cash, it may be a a good idea to sell some MRK shares to buy more of this underpriced gem than you received in the spin-off.
Just an opinion. No promises, etc., etc.
Recent MRK News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2026 05:24:06 PM
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 05/29/2026 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 08:15:25 PM
- Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care • PR Newswire (Canada) • 05/28/2026 01:00:00 PM
- Merck félicite le gouvernement de l'Ontario d'avoir élargi le champ d'activité des pharmaciens pour améliorer l'accès aux soins • PR Newswire (Canada) • 05/28/2026 01:00:00 PM
- Merck to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/28/2026 10:45:00 AM
- Merck Announces Third-Quarter 2026 Dividend • Business Wire • 05/26/2026 05:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:21:18 PM
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer • Business Wire • 05/22/2026 11:55:00 AM
- Synergis Software lance Adept Cloud, une plateforme de gestion de documents d'ingénierie native du nuage conçue pour les industries à forte intensité d'actifs • PR Newswire (Canada) • 05/21/2026 05:42:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/21/2026 10:02:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2026 08:23:39 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (Canada) • 05/20/2026 03:02:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/20/2026 03:02:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:14:07 PM
- Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer • Business Wire • 05/18/2026 10:45:00 AM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:06:47 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026 • Business Wire • 05/12/2026 10:45:00 AM
- Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate • Business Wire • 05/07/2026 06:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:18:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:10:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:07:01 PM
